BNP PARIBAS ARBITRAGE/PUT/ELI LILLY & CO/1000/0.01/20.09.24 | Real-time Borsa Italiana 05:22:44 2024-07-16 am EDT | ||
| 0.692 EUR | +3.28% |
|
| Current month | -30.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.692 | +3.28% |
| 24-07-15 | 0.67 | -2.62% |
| 24-07-12 | 0.688 | -10.65% |
| 24-07-11 | 0.77 | +1.45% |
| 24-07-10 | 0.759 | -2.82% |
Real-time Borsa Italiana
Last update July 16, 2024 at 05:22 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P24IM1 | |
| ISIN | NLBNPIT24IM1 |
| Date issued | 2024-06-27 |
| Strike | 1,000 $ |
| Maturity | 2024-09-20 (67 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.17 € |
|---|---|
| Lowest since issue | 0.599 € |
| Spread | 0.126 € |
| Spread % | 16.91% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5
USD
Average target price
893.1
USD
Spread / Average Target
-6.04%
- Stock Market
- Warrants
- P24IM1 Warrant
